Actively Recruiting
Renal Ultrasound Response After Chocolate Consumption
Led by Gregoire Wuerzner; MD · Updated on 2026-01-23
32
Participants Needed
2
Research Sites
188 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The consumption of dark chocolate (DC) has antihypertensive (3) and anti-inflammatory effects. Some studies also suggest that dark chocolate may also have cardiovascular benefits, but its physiological effects on the kidneys have not been studied in detail. In this randomized, single-blinded, controlled, monocentric cross-over study we will investigate whether the ingestion of a single dose of dark chocolate (g/kg, max 70g) leads to alterations in renal perfusion and blood pressure two hours after its consumption in healthy volunteers and patients suffering from chronic kidney disease. The Doppler-ultrasound assessed renal resistive index (RRI) will be used at baseline and two hours after chocolate consumption as an indirect measure of renal perfusion. Blood pressure and heart rate will be measured continuously using the Finapres® NOVA (Finapres Medical Systems, Enschede, The Netherlands) throughout the Doppler ultrasound examination. In order to compare the effects of dark chocolate with those obtained with white chocolate, participants will undergo a similar sequence of exames after the consumption of white chocolate.
CONDITIONS
Official Title
Renal Ultrasound Response After Chocolate Consumption
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Ability to understand the study protocol and provide informed consent
- For CKD patients: diagnosed with chronic kidney disease stage 1 to 3
You will not qualify if you...
- Lactose or cocoa intolerance
- Diabetes
- Severe digestive issues or liver disease
- History of kidney stones
- Inability to follow study procedures (e.g., due to language problems or dementia)
- Pregnancy
- Healthy volunteers taking antihypertensive medication
- Healthy volunteers with known kidney malformation or abnormality
- Healthy volunteers with albuminuria or hematuria in urine
- CKD patients with eGFR below 30 ml/min/1.73m2
- CKD patients with potassium level above 5.5 mmol/l in the last three months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Department of Nephrology, Centre Hospitalier Universitaire Vaudois
Lausanne, Canton of Vaud, Switzerland, 1011
Actively Recruiting
2
University Hospital of Lausanne (CHUV)
Lausanne, Canton of Vaud, Switzerland, 1011
Actively Recruiting
Research Team
M
Menno Pruijm, PD MD
CONTACT
W
Wendy Brito, radiological technician
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here